iSpecimen Inc..
ISPC.US | Other professional, scientific and technical activities n.e.c.
iSpecimen Inc. operates an online marketplace for human biospecimens, connecting researchers with a network of biobanks and healthcare organizations. The company facilitates the procurement of various biospecimens, including blood, plasma, serum, tissue, and other bodily fluids, along with associate...Show More
Better Health for All
20
The company's core business of providing human biospecimens is entirely devoted to health improvement by supporting research for diseases such as COVID-19, including variant identification, transmissibility, outcomes, and testing validity.
1
It also supports women's health research for conditions like cervical, uterine, and breast cancers, reproductive health, cardiovascular disease, autoimmune disorders, and STIs.
2
There is no evidence of revenue from products with negative health outcomes. The company's services do not have direct safety implications for physical or mental health. The privacy policy, updated May 18, 2018, details data security measures, including protection from loss, misuse, and unauthorized access, and states that data is processed in accordance with US Privacy Act and EU GDPR regulations.
3
The company also emphasizes automatic de-identification of patient data and adherence to HIPAA.
4
During the COVID-19 pandemic, the company supplied critical human biospecimens, including 600 SARS-CoV-2-positive serum samples and 100 negative serum samples, to the U.S. government and private researchers for advanced research phases.
5
Fair Money & Economic Opportunity
0
No evidence available to assess iSpecimen Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data was found across the provided articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. While executive compensation for the CEO was reported at $437,500 in 2023,
1
median employee compensation was explicitly stated as unavailable, preventing the calculation of the CEO-median pay ratio.
2
Employee reviews provided qualitative feedback and ratings on a 5-star scale for aspects like work-life balance (3.4-4.0), pay and benefits (2.8-3.1), and overall satisfaction (2.8-3.4),
3
but these are not directly convertible to the 0-100 engagement index required by the rubric. There was also a mention of a 20% headcount reduction in September 2023
4
and a 60% layoff mentioned in one review,
5
but no data on voluntary employee turnover rate. No information was available for living wage coverage, collective bargaining, safety incident rates, pay equity, labor violation incidents, insecure contract share, or health insurance coverage.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points or relevant information regarding ISPC.US's performance on Fair Trade & Ethical Sourcing KPIs were found in the provided articles.
1
All articles explicitly stated that no data was found for the requested metrics.
2
Honest & Fair Business
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Honest & Fair Business for ISPC.US.
1
The articles either did not mention the company in relation to the KPIs, explicitly stated that information was not available,
2
or were throttled and could not provide content.
3
Kind to Animals
0
iSpecimen Inc. operates an online marketplace for human biospecimens. Its core business model, as described, does not involve animal testing, animal agriculture, or the use of animal-derived ingredients. The provided articles discuss general industry trends, regulatory changes (such as the FDA's phase-out of animal testing requirements for mAbs by 2025
1
and the 2022 Modernization Act allowing non-animal technologies
2
), and the development of alternative testing methods (like NAMs, in vitro, and in silico models). However, none of the articles provide specific, concrete evidence or data points directly attributable to iSpecimen Inc.'s own operations, policies, investments, or engagement regarding any of the 'Kind to Animals' KPIs. Therefore, all KPIs must be omitted due to a lack of direct evidence for the company.
No War, No Weapons
0
The provided articles focus on iSpecimen Inc.'s biospecimen marketplace, detailing aspects such as researcher access, specimen quality, and biorepository sustainability. No information was found regarding the company's revenue from arms or defense contracts, investment in dual-use technologies, sales to embargoed regimes, peacebuilding initiatives, divestment policies for conflict zones, board oversight of defense activities, export end-user certificates, lobbying on arms control, humanitarian procurement standards, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use item screening, surveillance transparency, ethical red lines, exposure to controversial weapons, war-related supply chain risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace technology investment, or procurement from conflict-affected areas. One article explicitly stated that data retrieval was prevented due to throttling.
1
Planet-Friendly Business
0
No evidence was found in the provided articles to assess ISPC.US against any of the 'Planet-Friendly Business' KPIs. The articles either discussed unrelated topics, were inaccessible, or explicitly stated that no information regarding environmental sustainability or planet-friendly business practices was present. listed potential sources for ESG data but did not provide any actual quantitative or qualitative data points.
1
Respect for Cultures & Communities
0
No evidence available to assess iSpecimen Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
10
The company has no documented incidents of unauthorized data use. It provides users with control over their personal data by obtaining consent from donors and allowing data subjects to withdraw consent for data retention.
1
Privacy is integrated into product development through ethical collection practices and the automatic de-identification of patient data upon reception.
2
Data minimization is practiced by automatically de-identifying patient data before it is received from specimen partners.
3
The company adheres to regulations including 45 CFR part 46, HIPAA, 21CFR Part 50/56, the Uniform Anatomical Gift Act, the US Privacy Act of 1974, and GDPR, and conducts regular self-assessments to verify compliance.
4
Zero Waste & Sustainable Products
0
The provided articles do not contain any specific, concrete data points related to iSpecimen Inc.'s performance on Zero Waste & Sustainable Products KPIs. The 10-K report summary explicitly states an absence of data regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
One article discussed waste repurposing at a children's hospital, which is not relevant to iSpecimen Inc.
2